GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evolus Inc (NAS:EOLS) » Definitions » EPS without NRI

Evolus (Evolus) EPS without NRI : $-1.04 (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Evolus EPS without NRI?

Evolus's earnings per share without non-recurring items for the three months ended in Mar. 2024 was $-0.22. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.04.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 28.60% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 16.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Evolus's EPS without NRI or its related term are showing as below:

EOLS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -149.8   Med: 3.75   Max: 28.6
Current: 28.6

During the past 9 years, Evolus's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 28.60% per year. The lowest was -149.80% per year. And the median was 3.75% per year.

EOLS's 3-Year EPS without NRI Growth Rate is ranked better than
74.58% of 838 companies
in the Drug Manufacturers industry
Industry Median: 9.4 vs EOLS: 28.60

Evolus's EPS (Diluted) for the three months ended in Mar. 2024 was $-0.22. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.04.

Evolus's EPS (Basic) for the three months ended in Mar. 2024 was $-0.22. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.04.


Evolus EPS without NRI Historical Data

The historical data trend for Evolus's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolus EPS without NRI Chart

Evolus Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial Premium Member Only -3.19 -2.96 -1.30 -1.33 -1.08

Evolus Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.26 -0.32 -0.30 -0.20 -0.22

Competitive Comparison of Evolus's EPS without NRI

For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evolus's PE Ratio without NRI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evolus's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Evolus's PE Ratio without NRI falls into.



Evolus EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Evolus  (NAS:EOLS) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Evolus EPS without NRI Related Terms

Thank you for viewing the detailed overview of Evolus's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Evolus (Evolus) Business Description

Traded in Other Exchanges
Address
520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary of 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare, or commercial insurance. It generates product revenue from the sale of Jeuveau in the United States.
Executives
David Moatazedi director, officer: See Remarks C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Medytox Inc. 10 percent owner 78, GANGNI 1-GIL, OCHANG-EUP,, CHEONGWON-GU, CHEOGJU-SI M5 28126
Sandra Beaver officer: Chief Financial Officer 520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Tomoko Yamagishi-dressler officer: Chief Marketing Officer 520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Rui Avelar officer: See Remarks 1618 STATION STREET, VANCOUVER A1 V6A 1B6
Vikram Malik director 17901 VON KARMAN AVENUE, SUITE 150, IRVINE CA 92614
Alphaeon 1 Llc 10 percent owner 4040 MACARTHUR BOULEVARD, SUITE 310, NEWPORT BEACH CA 92660
Robert Hayman director 8550 HIGUERA ST, CULVER CITY CA 90232
Simone Blank director C/O SIRONA, WASSERFELDSTRASSE 30 A-5020, SALZBURG C4 5020
Peter C Farrell director RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Lauren P Silvernail officer: See Remarks 15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618
David N Gill director C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Crystal Muilenburg officer: Chief Marketing Officer 520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Brady Stewart director 520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Michael M. Jafar officer: Chief Marketing Officer 17901 VON KARMAN AVENUE, SUITE 150, IRVINE CA 92614